- Home
- FORA vs BOLD Comparison
FORA vs BOLD Comparison
Compare FORA & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FORA | BOLD |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | FORA | BOLD |
|---|---|---|
| Price | $2.14 | $1.27 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 26.7K | ★ 195.0K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,106,911.00 | N/A |
| Revenue This Year | $47.82 | N/A |
| Revenue Next Year | $10.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 37.47 | N/A |
| 52 Week Low | $1.64 | $1.00 |
| 52 Week High | $4.03 | $3.12 |
Technical Indicators
Market Signals| Indicator | FORA | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 52.46 |
| Support Level | $2.11 | $1.11 |
| Resistance Level | $2.19 | $1.27 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 47.06 | 67.84 |
Price Performance
Historical ComparisonAbout FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.